Skip to main content
. 2019 Oct 15;10(24):5915–5925. doi: 10.7150/jca.34564

Figure 5.

Figure 5

In silico analysis of the TCGA database concerning CAMK2N1 and WNT5A. A-C: Differential mRNA expression of CAMK2N1 according to pT stage (A), pN stage (B) and Gleason Score (C). D-F: Differential mRNA expression of WNT5A according to pT stage (D), pN stage (E) and Gleason Score (F). G - Disease/progression-free survival of prostate cancer patients according to CAMK2N1 alterations.